Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects [PDF]
Clinical and Molecular Hepatology, 2021 Hepatocellular carcinoma (HCC) is usually accompanied by chronic liver damage, which sometimes influences the selection of HCC treatment. The Barcelona Clinic Liver Cancer (BCLC) staging system, which was first introduced in 1999, is the most commonly ...
Takuji Torimura, Hideki Iwamoto
doaj +1 more source
Use of doxorubicin-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein invasion: a prospective study [PDF]
Journal of Liver Cancer, 2023 Background/Aim To evaluate the applicability of transarterial chemoembolization (TACE) treatment with doxorubicin drug-eluting beads (DEBs) in advanced hepatocellular carcinoma (HCC) patients with portal vein invasion (PVI).
Su Jong Yu +7 more
doaj +1 more source
Hepatocellular carcinoma with Budd-Chiari syndrome due to membranous obstruction of the inferior vena cava with long-term follow-up: a case report [PDF]
Journal of Liver Cancer, 2022 Membranous obstruction of the inferior vena cava (MOVC) is a rare subset of Budd-Chiari syndrome (BCS) with a subacute onset that is often complicated by cirrhosis and hepatocellular carcinoma (HCC).
Choong Hee Kim +9 more
doaj +1 more source
JGH Open, 2023 Background and Aim Transcatheter arterial chemoembolization (TACE) using various anticancer drugs is often performed to treat hepatocellular carcinoma (HCC).
Hironobu Ihira +12 more
doaj +1 more source
Ultraselective conventional transarterial chemoembolization: When and how? [PDF]
Clinical and Molecular Hepatology, 2019 Ultraselective conventional transarterial chemoembolization (cTACE), defined as cTACE at the most distal portion of the subsubsegmental hepatic artery, is mainly performed for hepatocellular carcinoma (HCC) ≤5 cm.
Shiro Miyayama
doaj +1 more source
Clinical outcomes of patients with a single hepatocellular carcinoma less than 5 cm treated with transarterial chemoembolization [PDF]
The Korean Journal of Internal Medicine, 2019 Background/Aims Transarterial chemoembolization (TACE) is performed for single hepatocellular carcinoma (HCC) that are not eligible for surgery or ablation therapy.
Min Young Baek +14 more
doaj +1 more source
The Korean Journal of Gastroenterology, 2020 Background/Aims: A switch to systemic therapy, such as sorafenib, should be considered for hepatocellular carcinoma (HCC) patients refractory to transarterial chemoembolization (TACE).
Kang Hyun Park +10 more
doaj +1 more source
Technology in Cancer Research & Treatment, 2022 Introduction: This retrospective study aimed to compare the efficacy and safety of transarterial chemoembolization plus lenvatinib and programmed death 1 (PD-1) inhibitors versus transarterial chemoembolization plus lenvatinib or sorafenib in patients ...
Shu Zhao MD +6 more
doaj +1 more source
The value of ADC calculations in the assessment of the early response of hepatocellular carcinoma (HCC) to trans arterial catheter chemoembolization (TACE). [PDF]
Minia Journal of Medical Research, 2019 Transcatheter arterial chemoembolization (TACE) is a well-accepted method for Treatment of unresectable hepatocellular carcinoma (HCC). Determining the success of treatment by imaging studies would help to guide subsequent therapeutic planning ...
Kareem Megahed +2 more
doaj +1 more source
World Journal of Surgical Oncology, 2021 Background Transcatheter arterial chemoembolization has been widely used in patients with hepatocellular carcinoma. However, double blood supply and the existence of portal vein tumor thrombus influence the efficacy of transcatheter arterial ...
Zhiying Shao +4 more
doaj +1 more source